web analytics
1.9 C
Sunday, December 4, 2022

Sunshine Biopharma, Inc. (OTCMKTS:SBFM) Bombaykid Steps in to Save the Day

Sunshine Biopharma, Inc. (OTCMKTS:SBFM) is making an explosive move up on accelerating volume since reversing off $0.0121 lows last week. The stock does have a history of big moves running from well under $0.25 to highs over $1.25 in 2011.

The current move up is a huge welcome to long suffering shareholders who have endured years of steady decline and the loss of well over 90% in the stock price.

Sunshine Biopharma, Inc. (OTCMKTS:SBFM) is focused on the research, development and commercialization of drugs for the treatment of various forms of cancer. According to SVFM their lead anti-cancer compound, Adva-27a, is currently in late stage preclinical studies.

Adva-27a is a Topoisomerase II inhibitor, small molecule that has recently been shown to be effective at killing Multidrug Resistant Breast Cancer cells, Small-Cell Lung Cancer cells, Uterine Sarcoma cells and Pancreatic Cancer cells (Published in ANTICANCER RESEARCH, Volume 32, Pages 4423-4432, October 2012).

Adva-27a is currently in the IND-Enabling stage of development. The original U.S. patent covering Adva-27a was issued on August 7, 2012 under U.S. patent number 8,236,935. The Company is planning a Phase I clinical trial of Adva-27a for Pancreatic Cancer in parallel to the Phase I clinical trial of Adva-27a for multidrug resistant Breast Cancer to be conducted at McGill University’s Jewish General Hospital in Montreal (Canada).

On March 24 SBFM announced that a “Notice of Allowance” for the patent application covering its lead antitumor compound, Adva-27a, has recently been issued in India. The allowed claims in India are nearly identical to those already issued in the United States (US Patent Number 8,236,935) where Sunshine Biopharma is the exclusive licensee. In addition to the U.S. and India, Adva-27a patents are issued in Europe and Canada.

Sunshine Biopharma has previously announced preclinical results showing that Adva-27a has excellent pharmacokinetics profile in rats and remarkable cytotoxic activity against a variety of multidrug resistant cancer cells including breast cancer cells and pancreatic cancer cells. Adva-27a appears to be unique in its ability to destroy multidrug resistant cancer cells. The GMP manufacturing of two kilograms of Adva-27a for clinical trials is currently underway at LONZA LTD in Switzerland. Sunshine Biopharma is planning to conduct the clinical trials of Adva-27a at McGill University’s Jewish General Hospital in Montreal, Canada. All aspects of the clinical trials in Canada will be performed in accordance with FDA approved protocols for direct filing of the results in the U.S.

CEO Dr. Steve N. Slilaty stated “Allowance of the Adva-27a patent application in India represents an achievement of a major milestone in our efforts to protect the proprietary nature of this unique anticancer compound. In addition to a market comprised of a population of over 1.2 billion people, India is a major participant in the manufacturing and exportation of pharmaceutical products and raw materials around the world.”

To Find out the inside Scoop on SBFM Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

SBFM traded for well over $1 in 2011 and was over $0.25 for most of 2012 as many investors put significant money into this stock because they believed in Dr. Steve N. Slilaty and his vision for Adva-27a.

This vision never came to fruition however and SBFM collapsed as insiders cashed in their chips and let the stock drift into oblivion decimating the original shareholder’s investment in the Company.

The result is a large group of investors who were wiped out by SBFM and are understandably very angry with Dr. Steve N. Slilaty who was recently seen driving about town in his new black BMW M6 convertible.

As SBFM hit its lowest point just over a penny Bombaykid stepped in to save the day stating ”that is not true, i work for lonza in india and sunshine pharma just bought a 10,000square feet facility, i will be working for it sunshine plant in india me very happy. Veri good news come out next week say doct karithe, veri powerful in india, doct karithe veri veri smart. Very very cheap, me buy cheap low, keep high india smart buiness peoples.”

Bombaykid certainly seems to have the magic touch with a significant acceleration of price and volume right after he appeared. In fact, ever since Bombaykid came in to save the day SBFM stock has reversed from its years long downtrend and is moving up on record breaking volume.

We have a Monster Pick Coming. Subscribe Right Now!

Currently trading at a $2 million market valuation SBFM has little assets and no revenues to date. From a technical standpoint SBFM looks promising with the recent explosion in price and volume after years of steady decline. We will be updating on SBFM when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with SBFM.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: we hold no position in SBFM either long or short and we have not been compensated for this article.

More articles


Please enter your comment!
Please enter your name here

Latest article

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.